Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

268

total

1598

impact factor

5.96

average impact factor

Group Leaders: Mª Jesús Cruz Carmona and Jaume Ferrer Sancho

team

zoom

download

The Group of Pneumology is a partner of the EXIMIOUS project. This project is part of the European Human Exposome Network and brings together 15 partner organizations from 7 European countries. In the area of environmental diseases there are various active projects such as the study of interaction between air pollution and asthma. Regarding lung transplant, we are developing several projects linked to our lung transplant biobank. We are going to study the microbiome of lung transplant patients and the role of cell free DNA. In sleep apnea and ventilation, projects include several multicenter studies to find out the impact of sleep apnea on the pediatric population. Regarding COPD, the group will coordinate a multicenter project to know the effectiveness of palliative cures in the final phases of the disease, and a project for the study of pathogenesis of COPD using molecular and computational biology techniques. The group is part of the Catalonian Referral Unit for Cystic Fibrosis, which maintains the Spanish registry of bronchiectasis and patients with a1-antitrypsin deficit.

99

total

537

impact factor

5^.42

average impact factor

SELECTED ARTICLES

Ojanguren I, Morell F, Ramon MA, Villar A, Romero C, Cruz MJ, Munoz X.
The immunomodulatory effects of diesel exhaust particles in asthma.
Environ Pollut 2020;263(Pt A):114600.
DOI: 10.1016/j.envpol.2020.114600
IF: 6.79
Masa JF, Mokhlesi B, Benítez I, Mogollon MV, Gomez de Terreros FJ, Sánchez-Quiroga MÁ, Romero A, Caballero-Eraso C, Alonso-Álvarez ML, Ordax-Carbajo E, Gomez-Garcia T, González M, López-Martín S, Marin JM, Martí S, Díaz-Cambriles T, Chiner E, Egea C, Barca J, Vázquez-Polo FJ, Negrín MA, Martel-Escobar M, Barbe F, Corral J; Spanish Sleep Network.
Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial.
Am J Respir Crit Care Med 2020;201(5):586-597.
DOI: 10.1164/rccm.201906-1122OC
IF: 17.45
Chalmers JD, Laska IF, Franssen FME, Janssens W, Pavord I, Rigau D, McDonnell MJ, Roche N, Sin DD, Stolz D, Suissa S, Wedzicha J, Miravitlles M.
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline.
Eur Respir J 2020;55(6):2000351.
DOI: 10.1183/13993003.00351-2020
IF: 12.34
van Ingen J, Aliberti S, Andrejak C, Chalmers JD, Codecasa LR, Daley CL, Hasegawa N, Griffith DE, Hoefsloot W, Huitt G, Jarand J, Jhun BW, Loebinger MR, Marras TK, Morimoto K, Polverino E, Ringshausen FC, Santin M, Thomson R, Wagner D, Wallace RJ, Winthrop KL, Yim JJ; NTM-NET.
Management of drug toxicity in M. avium complex pulmonary disease – an expert panel survey.
Clin Infect Dis 2020;ciaa1361.
DOI: 10.1093/cid/ciaa1361
IF: 8.31
Arjona-Peris M, Revilla-López E, Berastegui C, Sáez-Giménez B, Barrecheguren M, Bravo C, Monforte V, Bello I, Sacanell J, Burgos J, López Meseguer M.
Lung Transplant in HIV-Infected Patients. Single Centre Experience.
The Journal of Heart and Lung Transplantation 2020; 39:S81 – S82.
DOI: 10.1016/j.healun.2020.01.1306
IF: 7.87

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leaders: Mª Jesús Cruz Carmona and Jaume Ferrer Sancho

Research Areas